Results 11 to 20 of about 10,024 (235)

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial [PDF]

The Lancet, 2022
BackgroundThe safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19.
Butler, Christopher, IRVING, GREG, PANORAMIC Trial Collaborative Group‡   +2 more
core   +3 more sources

Molnupiravir: Mechanism of action, clinical, and translational science

Clinical and Translational Science
Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP).
Brian M. Maas, Julie Strizki, Randy R. Miller, Sushma Kumar, Michelle Brown, Matthew G. Johnson, Mickie Cheng, Carisa De Anda, Matthew L. Rizk, Julie A. Stone   +9 more
doaj   +2 more sources

A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus

Pulmonary Therapy
Introduction Human respiratory syncytial virus (RSV) infections can result in hospitalization and/or death among vulnerable populations. Molnupiravir is a prodrug of ß-D-N4-hydroxycytidine, which has broad-spectrum preclinical activity against RNA ...
Mickie H. Cheng, Alex J. Mann, Brian M. Maas, Tian Zhao, Melissa Bevan, Andrea K. Schaeffer, Laura E. Liao, Andrew P. Catchpole, David W. Hilbert, S. Aubrey Stoch, Carisa S. De Anda   +10 more
doaj   +2 more sources

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients [PDF]

, 2022
Little is known about SARS-CoV-2 evolution under Molnupiravir and Paxlovid, the only antivirals approved for COVID-19 treatment. By investigating SARS-CoV-2 variability in 8 Molnupiravir-treated, 7 Paxlovid-treated and 5 drug-naive individuals at 4 time ...
Alteri, Claudia, Bernardi, Stefania, Bernaschi, Paola, Burastero, Giulia Jole, Campana, Andrea, Costabile, Valentino, Esperti, Sara, Faltoni, Matteo, Fini, Vanessa, Fontana, Beatrice, Fox, Valeria, Franceschini, Erica, Gallerani, Altea, Granaglia, Annarita, Guaraldi, Giovanni, Meschiari, Marianna, Mussini, Cristina, Perno, Carlo Federico, Russo, Cristina, Scutari, Rossana, Villani, Alberto, Volpi, Sara   +21 more
core   +7 more sources

Computational Analysis of Molnupiravir [PDF]

International Journal of Molecular Sciences, 2022
In this work, we report in-depth computational studies of three plausible tautomeric forms, generated through the migration of two acidic protons of the N4-hydroxylcytosine fragment, of molnupiravir, which is emerging as an efficient drug to treat COVID-19. The DFT calculations were performed to verify the structure of these tautomers, as well as their
Artem Sharov, Tatyana Burkhanova, Tugba Taskın Tok, Maria Babashkina, Damir Safin   +4 more
openaire   +3 more sources

Molnupiravir: coding for catastrophe [PDF]

Nature Structural & Molecular Biology, 2021
Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as ‘lethal mutagenesis’. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the fidelity of SARS-CoV-2 genome replication
Brandon, Malone, Elizabeth A, Campbell
openaire   +2 more sources

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

New England Journal of Medicine, 2021
Background New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ...
Angélica Jayk Bernal, Monica M. Gomes da Silva, D. Musungaie, E. Kovalchuk, Antonio González, Virginia Delos Reyes, Alejandro Martín-Quirós, Y. Caraco, A. Williams-Diaz, M. Brown, Jiejun Du, Alison Pedley, C. Assaid, J. Strizki, J. Grobler, H. Shamsuddin, R. Tipping, H. Wan, Amanda Paschke, J. Butterton, Matthew G. Johnson, Carisa De Anda   +21 more
semanticscholar   +1 more source

The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective

Качественная клиническая практика, 2022
Molnupiravir is an antiviral drug with a broad spectrum of activity against RNA viruses. The safety of molnupiravir in clinical trials with COVID-19 was analyzed.
A. L. Khokhlov, J. V. Rybachkova
doaj   +1 more source

Molnupiravir: First Approval [PDF]

Drugs, 2022
Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback Biotherapeutics for the prevention and treatment of Coronavirus disease 2019 (COVID-19).
openaire   +2 more sources

Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients on kidney replacement therapy: observational cohort study using the OpenSAFELY-UKRR linked platform and SRR database [PDF]

, 2022
Background: Patients on kidney replacement therapy (KRT; dialysis and kidney transplantation) are at the highest risk of severe outcomes from COVID-19.

core   +4 more sources